Vivek Ra­maswamy is div­ing in­to RNA, launch­ing a new biotech with Ar­bu­tus and a team of vets

Af­ter buy­ing up a big chunk of Ar­bu­tus’ $ABUS shares, Roivant CEO Vivek Ra­maswamy has cre­at­ed a new joint ven­ture start­up that brings some top in­dus­try vet­er­ans to­geth­er with a mix of RNA-re­lat­ed tech­nolo­gies to launch a new com­pa­ny that will now build up a pipeline.

In a twist for Ra­maswamy, his new ven­ture — Genevant Sci­ences — doesn’t in­volve in-li­cens­ing a late-stage ther­a­py with an eye to­wards a quick flip to piv­otal da­ta. This time he’s tak­ing tech from Ar­bu­tus and build­ing a pipeline from scratch. But he still plans to move fast in­to a field of deeply ex­pe­ri­enced ri­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER